Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 5/20 | 0.50 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3346015 | 0.86 | GLS (0.54) | GLSBRD4KDM4ACTSKCREBBP | |
| SCHEMBL5261267 | 0.83 | GLS (0.51) | GLSBRD4KDM4ACTSKCREBBP | |
| SCHEMBL5264017 | 0.83 | GLS (0.51) | GLSBRD4KDM4ACTSKCREBBP | |
| SCHEMBL25908751 | 0.83 | GLS (0.51) | GLSBRD4KDM4ACTSKCREBBP | |
| SCHEMBL21455404 | 0.82 | GLS (0.54) | GLSBRD4KDM4ACTSKCREBBP | |
| SCHEMBL8342682 | 0.82 | GLS (0.55) | GLSBRD4KDM4ACREBBPNAMPT | |
| SCHEMBL1165088 | 0.82 | GLS (0.55) | GLSBRD4KDM4ACREBBPNAMPT | |
| SCHEMBL30069429 | 0.82 | GLS (0.55) | GLSBRD4KDM4ACREBBPNAMPT | |
| SCHEMBL16181822 | 0.82 | GLS (0.55) | GLSBRD4KDM4ACTSKCREBBP | |
| SCHEMBL13981921 | 0.82 | GLS (0.55) | GLSBRD4KDM4ACTSKCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | GLS 308/4885BRD4 1106/4885KDM4A 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.